Ocular Therapeutix, Inc. (OCUL) Financial Analysis & Valuation | Quarter Chart
Ocular Therapeutix, Inc. (OCUL)
OCULPrice: $8.79
Fair Value: 🔒
🔒score
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent... more
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and ... more
Description
Shares
| Market Cap | $1.91B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Pravin U. Dugel |
| IPO Date | 2014-07-25 | CAGR | 0.93% |
| Employees | 274 | Website | www.ocutx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
OCUL chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.58B | P/E Ratio | -6.19 |
| Forward P/E | -7 | PEG Ratio | — |
| P/S Ratio | 0.07 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.02 | P/FCF Ratio | -0.02 |
| EPS | $-1.42 | EPS Growth 1Y | 14.29% |
| EPS Growth 3Y | 41.18% | EPS Growth 5Y | -40.74% |
| Revenue Growth 1Y | -18.47% | Gross Margin | 0.87% |
| Operating Margin | -5.2% | Profit Margin | -5.12% |
| ROE | -0.72% | ROA | -0.33% |
| ROCE | -0.36% | Current Ratio | 15.39 |
| Quick Ratio | 15.32 | Cash Ratio | 14.51 |
| Debt/Equity | 0.12 | Interest Coverage | -22.82 |
| Altman Z Score | 5.27 | Piotroski Score | 2 |